Form 4: POAI Director Handley Granted 64,680 Restricted Stock Units

Predictive Oncology Inc. Director Daniel E. Handley received a grant of 64,680 restricted stock units, which are set to vest on October 31, 2025.

Summary

• Daniel E. Handley, a Director of Predictive Oncology Inc. (POAI), acquired 64,680 shares of common stock.
• The acquisition occurred on September 9, 2025, at a price of $0.00 per share.
• These shares are in the form of Restricted Stock Units (RSUs), where each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest in full on October 31, 2025, contingent upon Mr. Handley's continued service to the company.
• Following this transaction, Mr. Handley beneficially owns 81,698 shares of common stock directly.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard practice that aligns management's interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and retention.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the grant is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and retention of key personnel.

Negatives

• No negative aspects are directly reported in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The filing does not provide forward-looking statements or guidance beyond the vesting schedule of the granted restricted stock units.

Industry Context

This Form 4 filing reports a routine insider equity grant, a common practice across industries to incentivize and retain directors and executives by aligning their financial interests with company performance. It does not provide broader industry trend analysis.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs), are a standard component of executive and director compensation packages across publicly traded companies.
• The specific size of the grant (64,680 RSUs) for a director at Predictive Oncology Inc. would typically be evaluated against peer companies in the biotechnology or oncology sector, considering the company's market capitalization, stage of development, and overall compensation philosophy. Without specific peer data, a direct comparison is not feasible within this filing.

Related Party Transactions

• The RSU grant to Director Daniel E. Handley is a transaction between the company and a related party (director), which is disclosed as part of standard compensation practices.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially fostering better long-term decision-making.
• Management: The grant serves as an incentive for the director's continued service and performance.

Next Steps

• The 64,680 Restricted Stock Units are scheduled to vest in full on October 31, 2025, subject to continued service.

Key Dates

Keywords

Predictive Oncology Inc., POAI, Daniel E. Handley, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director compensation, beneficial ownership